Congress Materials - American Urological Association (AUA 2024)
2024 American Urological Association | May 3-6 | San Antonio, TX
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP): A Multicenter, Open-Label, Single-Arm Phase 2 Study
Neal Shore, Jason Hafron, Daniel Saltzstein, Gordon Brown, Laurence Belkoff, Pankaj Aggarwal, Jennifer Phillips, Amitabha Bhaumik, Tracy McGowan
MoonRISe-1: Phase 3 Study of TAR-210, an Erdafitinib Intravesical Delivery System, Versus Intravesical Chemotherapy in Patients With Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations
Roger Li, Gautam Jayram, Angela Girvin, Anne O’Hagan, Sabine D. Brookman-May, Jiao Song, Nicole Stone, Cateau Van Oevelen, Sydney Akapame, Neil Beeharry, Spyros Triantos, Benjamin Pradere
Real World Treatment Sequence and Survival in Localized or Locally Advanced Prostate Cancer and Postprogression Disease States
Stephen J. Freedland, Sandhya Nair, Xiwu Lin, Francesco De Solda, Ravi Potluri, Sharon A. McCarthy, Suneel D. Mundle, Neeraj Agarwal
SunRISe-2: A Phase 3, Multicenter, Randomized Study Evaluating the Efficacy of TAR-200 in Combination With Cetrelimab Versus Chemoradiotherapy in Patients With Muscle-Invasive Bladder Cancer
Steven B. Williams, Wolfgang Jessner, Meggan Tammaro, Marietta Kashmer, Jenna C. Carcione, Hussein Sweiti, Shahrokh F. Shariat
SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical Bacillus Calmette–Guérin in Patients With Bacillus Calmette–Guérin-Naïve High-Risk Non–Muscle-Invasive Bladder Cancer
Sam S. Chang, Andrea Necchi, Thomas Powles, Félix Guerrero-Ramos, Giuseppe Simone, Neal Shore, Jorge Salinas, Axel S. Merseburger, Mathieu Roumiguié, Hiroshi Kitamura, David Morris, Wei Qiang, Fernando Korkes, Mohamad Hasan, Vahid Naini, John Maffeo, Constance Hammond, Hussein Sweiti, Robert Somer, James WF Catto
SunRISe-5: A Phase 3, Randomized, Open-Label Study of TAR-200 Compared With Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent High-Risk Non-Muscle Invasive Bladder Cancer
Sima Porten, Sumeet Bhanvadia, Saltanat Najmi, Hussein Sweiti, John Maffeo, Katharine Stromberg, Benjamin Pradere
TAR-200 in Patients With Bacillus Calmette–Guérin-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From SunRISe-1 Study
Joseph M. Jacob, Andrea Necchi, Siamak Daneshmand, Giuseppe Simone, Evanguelos Xylinas, David S. Morris, Philipp Spiegelhalder, Daniel Zainfeld, Taek Won Kang, Justin T. Matulay, Laurence H. Belkoff, Karel Decaestecker, Harm Arentsen, Shalaka Hampras, Christopher J. Cutie, Hussein Sweiti, Katharine Stromberg, Jason Martin, Abhijit Shukla, Michiel S. van der Heijden
TAR-210 Erdafitinib Intravesical Delivery System in Non–Muscle-Invasive Bladder Cancer With Select FGFR Alterations: Updated First-in-Human Results
Antoni Vilaseca, Gautam Jayram, Carles Raventos, Neal D. Shore, Daniel Zainfeld, Taek Won Kang, Ja Hyeon Ku, Joshua J. Meeks, Óscar Rodríguez Faba, Florian Roghmann, Siamak Daneshmand, Neil Beeharry, Carrye R. Cost, Anna Kalota, Josh Lauring, Michelle R. Peterson, Michelle Quiroz, Nicole L. Stone, Wei Zhu, Felix Guerrero-Ramos
Copies of these presentations are for personal use only and may not be reproduced without permission from the author of this presentation.